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Abstract
Background: Teleoncology refers to the use of telemedicine for remotely providing multiple specialized services in clinical oncol-
ogy processes, including screening, diagnosis, treatment planning, consultation, supportive care, pathology, surgery, and follow-up
services.
Objectives: The aim of this study was to identify the required data elements and elicitation of requirements for developing a
telemedicine system that aims at providing treatment plans for patients with breast cancer.
Methods: In this study, the required data elements for the teleoncology system were identified through both the investigation of
clinical guidelines and review of patients’ medical records. Identified data elements were determined by breast cancer specialists
through the questionnaire. Besides, an interview method was applied to elicit the requirements of this system.
Results: The identified data elements were categorized into 20 groups (e.g., clinical data, breast physical examinations, patholog-
ical results, tests, imaging results, etc.). From the 182 data elements included within the questionnaire, 125 were recognized to be
necessary (n = 32, 100%). The lowest mean percentage were observed in magnesium blood test (Mg) (n = 21, 65.63%) and protein test
(Pr) (n = 21, 65.63%). Other data elements with a minimum mean of 71.87% and a maximum mean of 100% were recognized necessary.
In general, 2 major themes, 9 categories, and 45 related sub-categories were extracted from analyzing the findings of the interviews
related to the system requirements.
Conclusions: The findings of the present study can be used as a basis for developing teleoncology systems that aim at providing
treatment plans for patients with breast cancer.
Keywords: Telemedicine, Medical Oncology, Breast Neoplasm, Clinical Protocols
1. Background
As the most common type of cancer, breast cancer is
one of the leading causes of cancer-related deaths in Ira-
nian women (1, 2). Thus, it has a significant influence on
public health and is a key concern of health policymak-
ers (3, 4). In general, the global incidence of breast cancer
will be increasing, particularly in regions with a low rate of
incidence (5). In developing countries, in addition to the
growing incidence of breast cancer in recent decades, pa-
tients are often diagnosed in advanced stages (6). More-
over, costs associated with different stages of the cancer
treatment are rising rapidly, in such a way that even the
rich countries are faced with financial restrictions in pro-
viding high-quality care equally accessible for all their res-
idents (7). One of the most effective approaches to man-
aging the treatment process of patients with breast can-
cer is suggested to be the use of multidisciplinary teams
(8), which is not a new concept and is on the verge of
becoming a medical standard of care (9). Telemedicine,
a relatively new technique for healthcare delivery by us-
ing telecommunication technology, is one of the innova-
tive and appropriate tools that can be applied to increase
access to care services, overcome geographical barriers,
and provide remote healthcare services for such areas (10).
Telemedicine can make changes in processes of different
domains of healthcare, including prevention, diagnosis,
education, and treatment (11). Telepathology, teleophthal-
mology, teleradiology, and teleoncology are some of the
subsets of telemedicine that have been employed in var-
ious medical specialties (12). Teleoncology refers to the
use of telemedicine for remotely providing multiple spe-
cialized services in clinical oncology processes, including
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screening, diagnosis, treatment planning, consultation,
supportive care, pathology, surgery, and follow-up services
(13). In this regard, many studies on the implementation
of teleoncology have been performed for different types of
cancers, including breast cancer in several countries (14-
16).
The medical practice employs a combination of sci-
ence and art to prevent, diagnose, and treat diseases. How-
ever, applying this approach without using appropriate
guidelines will not guarantee the successful therapeutic
and diagnostic outcomes (17). Recently, several clinical
guidelines have been developed in the areas of preven-
tion, diagnosis, and treatment for a wide range of medi-
cal specialties including oncology (18). Some of these clini-
cal guidelines have been developed by professional organi-
zations to provide up-to-date quality and specific evidence
to assist clinicians in making decisions, better treatment
options, and designing optimal care pathways for patients
with breast cancer (19, 20). Therefore, it seems appropriate
to employ the relevant identified clinical guidelines when
a telemedicine system is used (21).
Every software system has requirements that should
be identified before the development and implementation
of the system because the success of a software system de-
pends on how it meets the needs of its users (22). There-
fore, determining the requirements of a software system,
using the requirements engineering process, is the initial
and fundamental stage in the design and development
process of a system (23). The primary outcome of system
requirements engineering is to determine the specifica-
tions of software systems achieved by investigating and an-
alyzing the needs of its stakeholders (24). Healthcare en-
vironments have multiple stakeholders with several back-
grounds and interests, including health professionals, pa-
tients, and managers. Moreover, software developed in the
healthcare domain is more unique and specific than other
software; so, the process of identifying the requirements of
these software needs to be taken more seriously and com-
prehensively (25, 26).
Digital health technologies including telemedicine as
a software system have considerably affected different as-
pects of healthcare delivery services by improving commu-
nication and facilitating data sharing between physicians
and patients (27). However, many telemedicine projects
have faced failure due to insufficient attention to the hu-
man, organizational, and other non-technological factors
affecting these projects during the design and implemen-
tation phases, particularly in the requirements engineer-
ing phase (28). Therefore, the requirements engineering
process for telemedicine projects, like any other software
project, is crucial to identify its requirements (29).
2. Objectives
The aim of this study was to identify the required data
elements (the data used by physicians to make decisions
about presenting treatment plans to patients) and deter-
mine what requirements are needed and how to identify
them for implementing a telemedicine system to provide
treatment plans for patients with breast cancer.
3. Methods
3.1. Identifying the Required Data Elements
In this study, data elements required in the
telemedicine system to provide treatment planning
for patients with breast cancer were identified and de-
termined in 3 stages. Firstly, validated clinical guidelines
related to the provision of treatment plans for patients
with breast cancer were examined and the related data
elements were, then, extracted. Guidelines that were
considered in this research were as follow:
1. Clinical Guidelines for the Management of Breast
Cancer (West Midlands Expert Advisory Group for Breast
Cancer) (30).
2. National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines in Oncology (NCCN Guide-
lines) Breast Cancer (31).
3. St. Gallen/Vienna 2019: A Brief Summary of the Con-
sensus Discussion on the Optimal Primary Breast Cancer
Treatment (32).
4. Primary breast cancer: European Society for Medical
Oncology (ESMO) Clinical Practice Guidelines for diagnosis
treatment and follow-up (33).
5. 4th European School of Oncology-European Society
for Medical Oncology (ESO-ESMO) International Consensus
Guidelines for Advanced Breast Cancer (ABC 4) (34).
In addition to the clinical guidelines mentioned above,
the clinical guidelines related to breast cancer in Iran, the
clinical guideline for early detection of breast cancer devel-
oped by the Deputy of Treatment, Ministry of Health and
Medical Education of Iran (35), was reviewed to identify the
data elements associated with the diagnosis of breast can-
cer.
In the second step, several medical records of patients
with breast cancer, receiving different treatment plans
were examined. To meet the objectives of the study, the au-
thors extracted the data elements, which were used by the
physicians to develop the treatment plans.
In the third step, a questionnaire was designed based
on the integration of data extracted from the previous
steps. Then, the questionnaire was evaluated for reliabil-
ity and validity (face and content validity). In doing so, re-
liability was evaluated, using Kuder Richardson 21 (KR-21).
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However, the qualitative method was used to determine
face validity, which was determined by forming a special-
ized panel comprised of 4 breast oncologists. In this panel,
the difficulty level of questions, the use of common and rel-
evant terms in the field, the amount of mismatch, the am-
biguity of the concepts, phrases and expressions, and word
meaning were appraised and discussed. Afterward, their
comments were applied to the questionnaire.
Content validity was assessed through qualitative and
quantitative methods. In the qualitative content valid-
ity method, 5 breast oncologists different from the men-
tioned 4-person panel were asked to propose their correc-
tive opinion in written form after a careful study of the
questionnaire. It was further emphasized that in assess-
ing the quality of content validity, the following criteria
were taken into account: the grammar, use of appropri-
ate words, importance and relevance of questions, the or-
der of questions, and the time needed to complete the
questionnaire. The necessary changes were made to the
questionnaire after collecting the experts’ opinions. Then,
the Content Validity Ratio (CVR) and Content Validity In-
dex (CVI) were used to evaluate the content validity of the
questionnaire by breast oncologists. In doing so, 8 copies
of the questionnaire were given to radiation oncologists
to rate each item of the questionnaire for measuring the
CVR (based on 3-point scales: “necessary”, “useful but not
necessary”, and “not necessary”) and the CVI (based on 4-
point scales: “an irrelevant item”, “relevant but needs mi-
nor revision”, “relevant but needs serious revision”, and
“extremely relevant item”).
Responses to the items of the questionnaire were ana-
lyzed based on the CVR formula and were compared with
the Lawshe table. Values above 75% were accepted for each
item of the questionnaire (36). After measuring and deter-
mining CVR, the CVI of the survey was determined accord-
ing to the Waltz and Basel content validity index. Then,
based on the CVI results, each item in the questionnaire
with a value above 79% was accepted (37). Ultimately, the fi-
nal version of the questionnaire was distributed among 45
breast cancer specialists, who had at least 5 years of clinical
experience for receiving their viewpoints and determining
the data elements required to design treatment plans.
The final version of the questionnaire consisted of 2
parts with a total of 186 questions, including respondents’
demographic information (4 questions) and required data
elements for providing treatment plans (182 questions).
The second part of the questionnaire was divided into 20
sub-categories according to the type of data included. To
determine the required data elements based on the re-
sponses obtained from breast specialists, researchers of
this study assigned two options of “necessary” (one point)
and “unnecessary” (zero points) to each question. Addi-
tionally, a blank space was provided at the end of each sub-
category for receiving comments and other required data
elements from the perspective of respondents.
3.2. Requirements Elicitation
In this study, an interview method was applied to
elicit the requirements of a teleoncology system to pro-
vide treatment planning for patients with breast cancer.
Subsequently, both quantitative and qualitative data were
obtained. Using this method made it possible to have a
deeper analysis of stakeholders’ feedback and needs.
3.2.1. Data Collection Tool
The initial interview guide was prepared based on the
literature review (11, 12, 38, 39). Afterward, the final version
of the interview guide was prepared, content and face va-
lidity of the interview questions were approved by using
in-depth interviews with 3 experts in the field of health in-
formation management, medical informatics, and breast
cancer treatment. The final interview guide included 2
main open questions about functional and non-functional
requirements. In this regard, definitions and examples
of such requirements were provided to learn more about
these requirements in the interview guide. Two main open
questions, used in our research, were as follow:
1. What do you think are the functional requirements
of the telemedicine system to provide treatment planning
for patients with breast cancer?
2. What do you think are the non-functional require-
ments of the telemedicine system to provide treatment
planning for patients with breast cancer?
Furthermore, the questionnaire included require-
ments identified from studies in the field of telemedicine
that were presented in the final interview guide to survey
participants. To investigate the views of participants on
the presented requirements, 2 options including “neces-
sary” (one point) and “unnecessary” (zero points) were
assigned to each question.
3.2.2. Data Collection Method
Face-to-face interviews were conducted with each of
the participants according to the schedule agreed at the
designated location by the researcher. A general explana-
tion of the study and its objectives were given to all in-
terviewees and written informed consent forms were ob-
tained from all of them before the beginning of the inter-
view. Moreover, the confidentiality of information gath-
ered from the interviews was emphasized, and it was an-
nounced that the information extracted from the inter-
views would be presented to them for approval. The in-
terviews were recorded in coordination with the intervie-
wees, and important details were noted by the researcher
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during the interview process. The interviews were contin-
ued until the data were saturated.
3.2.3. Data Analyzing Method
The information from the interviews was analyzed, us-
ing content analysis. For this purpose, all recorded audio
files were transcribed and completed by taking notes writ-
ten during the interviews. Subsequently, all documents
and information extracted from the interviews in the form
of text files were entered into the MAXQDA software to per-
form coding and qualitative analyses. Finally, the intervie-
wee’s suggestions and comments were extracted based on
the themes, categories and sub-categories, and interpreted
narratively.
4. Results
4.1. Results of Identifying the Required Data Elements
The results of the integration of data elements ex-
tracted from clinical guidelines and patients’ medical
records were presented as a questionnaire. Upon the de-
velopment of the initial questionnaire, the reliability and
validity were assessed and minor changes were applied. In
addition to partial changes in the arrangement of the data
elements, “ethnicity” was the only data element removed
from the initial questionnaire. Concerning CVI and CVR,
the total average score of 0.87 and a mean score of 0.89, re-
spectively, was obtained. The total inter-item reliability of
the questionnaire was measured by KR-21 (ρKR21 = 0.81).
Overall, 45 questionnaires were distributed among ra-
diation oncologists (n = 27), gynecologists (n = 6), special-
ists in blood and adult cancers (n = 6), and cancer sur-
geons (n = 6) working in hospitals and healthcare facili-
ties. The total participation rate of specialists to fill out the
questionnaire was 71.11%, including radiation oncologists
(n = 19, 70.37%), gynecologists (n = 4, 66.66%), specialists
in blood and adult cancers (n = 5, 83.33%), and cancer sur-
geons (n = 4, 66.66%). The mean age of specialists was 46.13
±5.41 years, and the meaningful work experience was 12.59
± 6.08 years. The mean percentage of respondents regard-
ing the required data elements to provide treatment plans
for patients with breast cancer are shown in Tables 1-5.
Overall, form 182 data elements in the questionnaire,
125 were unconditionally considered necessary (n = 32,
100%) from the experts’ point of view. Based on the data
in Tables 1-5, the lowest mean percentages are related to
the magnesium blood test (Mg) (n = 21, 65.63%) and protein
test (Pr) (n = 21, 65.63%). Other data elements in these tables
range from 71.87% to 100%, which was considered necessary
by experts.
4.2. Results of the Requirements Elicitation
As mentioned earlier, one of the aims of the present
study was to identify the requirements of the teleoncology
system to provide treatment plans to patients with breast
cancer by using the interview method. Overall, 15 quali-
fied specialists in the field of breast cancer treatment (hav-
ing at least 3 years of clinical experience in providing treat-
ment plans for patients with breast cancer), as well as 10
qualified faculty members of health information manage-
ment and medical informatics (having at least 3 years of
faculty experience and familiar with software information
systems) were invited to participate in the interview. The
interviews continued until the saturation of the data were
obtained, with 18 experts participating in the interview.
The average interview time was 30 minutes.
In total, 18 interviews were conducted with experts in
various disciplines, including health information manage-
ment (n = 4), medical informatics (n = 2), radiation oncol-
ogy (n = 8), pathology (n = 2), and cancer surgeon (n = 2).
The mean age of the respondents was 44.11±6.98 years and
most of them were males (n = 12, 66.66%). Moreover, most
of the interviewees were clinical specialists (n = 12, 66.66%),
who were radiation oncologists (n = 8, 44.45%).
As mentioned earlier, the interview guide was de-
signed in such a way that it included a basic frame-
work involved requirements that were pre-identified by
the researcher by reviewing related research and software
projects. All of these requirements were considered nec-
essary by all interviewees in the study as essential require-
ments for the teleoncology system. Subsequently, a total of
2 main themes, 9 categories, and 41 related sub-categories
were extracted from analyzing the findings of the inter-
views (Table 6).
5. Discussion
According to the review of the studies, no research
has been conducted in Iran regarding the implementa-
tion of telemedicine for oncology in breast cancer. How-
ever, many studies have been conducted on the use of
telemedicine in oncology for a variety of cancers (40-42),
including breast cancer in other countries (15, 43). In this
regard, the results of studies show that healthcare profes-
sionals generally support the use of telemedicine technol-
ogy in the field of oncology. Furthermore, the results of
studies have shown that the quality of medical services
provided to patients using this technology has been appro-
priate. Also, it is cost-effective and has reduced the cost
of healthcare systems (15, 16, 44, 45). Therefore, in addi-
tion to using conventional methods (face to face) to man-
age breast cancer treatment in some countries, the facili-
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Table 1. Patients’ Demographic Information and Clinical Data











10 Marital status 87.50
11 Job 81.25
12 Residential address 87.50
13 Patient contact number 87.50
2-Clinical data
14 The chief complaint 100
15 Symptoms other than the chief complaint 100
16 The first symptom leads to doubt 87.50
17 PS 100
18 Drugs in use 100
19 Drug used 100
20 Menstrual status 100
21 Age of first menstruation 87.50
22 Pregnancy status 100
23 Age of first pregnancy 87.50
24 Number of gravidities 81.25
25 Number of parities 75
26 Number of live births 75
27 Number of abortions 81.25
28 Menopause age 100
29 Lactation status 100
30 Contraception and its methods 100
31 Duration of diabetes (in years) 84.38
32 Medications used for diabetes (oral, insulin) 100
33 Cardiovascular disease 100
34 Hypertension 100
35 Immune deficiency disease 100
36 Patient’s other comorbidities 100
37 History of surgery 90.62
38 Collagen and vascular diseases 100
39 Personal history of malignancy 100
40 History of hormone therapy and its type 100
41 History of chemotherapy 100
42 History of radiotherapy 100
43 Previous treatment plans 100
44 Duration of smoking (in years) 87.50
45 Daily cigarette consumption (pack of cigarettes per day) 87.50
46 History and level of alcohol consumption (low, medium, high) 90.62
47 Family history of malignancy 100
48 History of hepatitis 78.13
49 AIDS 87.50
Abbreviations: BSA, body surface area; BMI, body mass index; PS, performance status; AIDS, acquired immunodeficiency syndrome
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Table 2. Examination of the Breast, Lymph Nodes, Distant Metastasis, and Chest Wall
Category Data Elements Average (%) Necessary
3-Physical examination of the breast
50 The results of a physical examination of the breast (detectable
mass?)
100
51 Location of the mass in the left breast (1. upper-outer, 2.
upper-inner, 3. lower-outer, 4. lower-inner, 5.central)
100
52 Location of the mass in the right breast (1. upper-outer, 2.
upper-inner, 3. lower-outer, 4. lower-inner, 5.central)
100
53 Size of breast mass (cm) 100
54 Fixation of the breast mass (yes, no) 100
55 Breast skin involvement (discoloration, scars, nodules, orange peel
skin)
100
56 Area of breast skin involvement (less than 30%, between 30% and
50%, more than 50%)
87.50
4-Examination of the lymph nodes
57 The results of the examination of the lymph nodes (detectable
mass?)
100
58 Location of enlarged lymph nodes (axilla, supraclavicular,
mammary internal)
100
59 Fixation of the lymph nodes (yes, no) 100
60 Size of the lymph node (cm) 100
61 Matted lymph nodes 100
5-Examination of distant metastasis
62 Results of distant metastasis examination (bone tenderness,
respiratory distress, ascites, organomegaly, etc.)
100
6-Breast examination (in case of the previous lumpectomy)
63 Evidence of local recurrence (left side [at the surgical scar site, away
from the surgical scar])
100
64 Evidence of local recurrence (right side [at the surgical scar site,
away from the surgical scar])
100
65 Type of local recurrence (ulcer, mass, discoloration) 100
66 Local recurrence size (cm) 100
67 Fixation of local recurrence (yes, no) 100
7-Chest wall examination (in case of the previous mastectomy)
68 Evidence of local recurrence (left side [at the surgical scar site, away
from the surgical scar])
100
69 Evidence of local recurrence (right side [at the surgical scar site,
away from the surgical scar])
100
70 Type of local recurrence (ulcer, mass, discoloration) 100
71 Local recurrence size (cm) 100
72 Fixation of local recurrence (yes, no) 100
ties and capabilities of telemedicine technologies are also
used as a tool to improve service delivery to patients.
5.1. Identifying the Required Data Elements
Teleoncology is a potential solution in the manage-
ment of breast cancer worldwide. It can establish effective
and systematic collaboration among healthcare providers
in multiple oncology centers for improving cancer care
services (46). Given that the development of such a system
is in its early stage in Iran, identifying required data ele-
ments is the first step in developing a telemedicine system
that aims at providing treatment plans for patients with
breast cancer. There are various treatment plans available
for patients with breast cancer and people suffering from
this type of cancer often receive more than one treatment
plan (47). Furthermore, selection of a treatment plan for
patients with breast cancer is based on many factors, in-
cluding the extent and location of the tumor (number and
extent of lymph node involvement, number of lesions, size
and location of the primary tumor), as well as age, patient’s
general health status, and patient’s preferences (33). There-
fore, the required data elements for the telemedicine sys-
tem were identified by investigating the clinical guidelines
and reviewing the medical records of patients with breast
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Table 3. Pathology of the Breast, Surgical, and Lymph Node Biopsy
Category Data Elements Average (%) Necessary
8-Pathology of breast and lymph node biopsy
73 Pathology of breast biopsy 100
74 Pathology of lymph node biopsy 100
9-IHC & FISH (or CISH) breast and lymph node biopsy
75 Date of biopsy 100
76 ER (negative or positive) (percent of + cells… Positivity: week, moderate,
strong)
100
77 PR5 (negative or positive) (percent of + cells… Positivity: week, moderate,
strong)
100
78 HER2 (-, +1, +2, +3) 100
79 Ki-67 100
80 E-cadherin (negative or positive) 84.38
81 HER2 FISH (or CISH) (amplified, not amplified) 100
82 Other performed IHCs 87.50
10-Surgical pathology
83 Date of surgery 100
84 Pathology of breast surgery 100
85 Pathology of lymph node surgery 100
86 Surgery: breast (breast conservation surgery, total mastectomy, radical
mastectomy, skin-sparing, nipple-sparing)
100
87 surgery: axillary (sentinel: negative [number of nodes removed]) 100
88 surgery: axillary (sentinel: positive [number of positive nodes and number of
nodes removed])
100
89 surgery: axillary (dissection: negative [number of nodes removed]) 100
90 surgery: axillary (dissection: positive [number of positive nodes and number
of nodes removed])
100
91 surgery: breast reconstruction (time: immediate or delayed) 100
92 surgery: breast reconstruction (type: prosthesis or autologous) 100
93 the number of tumor lesions 100
94 Size of the tumor (cm) 100
95 Skin involvement 100
96 Nipple involvement 100
97 LVSI 100
98 PNI 100
99 Extracapsular extension 100
100 Percentage of carcinoma in situ 100
101 Grade (1 or 2 or 3) 100
102 Margin status (R0, close, R1, R2) 100
11-IHC & FISH (or CISH) surgery
103 ER (negative or positive) (percent of + cells… positivity: week, moderate,
strong)
100
104 PR (negative or positive) (percent of + cells… positivity: week, moderate,
strong)
100
105 HER2 (-,+1,+2,+3) 100
106 Ki-67 100
107 E-cadherin (negative or positive) 100
108 HER2 FISH (or CISH) (amplified, not amplified) 100
109 Other performed IHCs 87.50
Abbreviations: CISH, chromogenic in situ hybridization; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor
2; IHC, immunohistochemistry; LVSI, lymphovascular space invasion; PNI, perineural invasion; PR, progesterone receptor
cancer in this study.
In some studies, identifying required data elements
for telemedicine systems has been performed by review-
ing the literature and designing a researcher-made ques-
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Table 4. Recurrent Pathology and Pathology of Metastatic Biopsy and Staging by Tumor-Node-Metastasis (T-N-M)
Category Data Elements Average (%) Necessary
12-Recurrent pathology
110 Pathology of breast recurrence 100
111 Pathology of lymph node recurrence 100
13-IHC & FISH (or CISH) recurrence
112 ER (negative or positive) (percent of + cells… positivity: week, moderate, strong) 100
113 PR (negative or positive) (percent of + cells… positivity: week, moderate, strong) 100
114 HER2 (-, +1, +2, +3) 100
115 Ki-67 100
116 HER2 FISH (or CISH) (amplified, not amplified) 100
117 Other performed IHCs 87.50
14-Pathology of metastatic biopsy
118 Pathology of distant metastasis 100
119 Pathology of lymph node metastasis 100
15-IHC & FISH (or CISH) metastasis
120 ER (negative or positive) (percent of + cells… positivity: week, moderate, strong) 100
121 PR (negative or positive) (percent of + cells… positivity: week, moderate, strong) 100
122 HER2 (-, +1, +2, +3) 100
123 Ki-67 100
124 HER2 FISH (or CISH) (amplified, not amplified) 100
125 Other performed IHCs 87.50
16-Staging by T-N-M
126 T (TX, Tis, T0, T1, T2, T3, T4 (T4a, T4b, T4c, T4d)) 100
127 By which modality the T was determined? (CT, MRI, Sonography, PET-Scan, Mammography,
Pathology, Examination)
100
128 N (NX, N0, N1, N2, N3) 100
129 By which modality the N was determined? (CT, MRI, Sonography, PET-Scan, Mammography,
Pathology, Examination)
100
130 M (M0, M1) 100
131 Metastasis location (bone, lung, liver, lymph nodes, brain, etc.) 100
132 Metastasis detection method (imaging (CT, MRI, Sonography, bone scan, PET-Scan) or biopsy) 100
133 The final result of staging (T-N-M) 100
Abbreviations: CT, computerized tomography; MRI, magnetic resonance imaging; PET-Scan, positron emission tomography-scan; T-N-M, tumor-nodes-metastasis
tionnaire for receiving the users’ opinions (11, 12, 48, 49).
However, for identifying the required data elements, this
study scrutinized the latest clinical guidelines related to
breast cancer and reviewed the medical records of patients
with breast cancer, who received different treatment plans.
Due to the multidisciplinary approach of the teams for
optimally managing patients with breast cancer, knowl-
edge, and views of healthcare providers with various spe-
cialties in oncology, including radiation oncologists, gyne-
cologists, blood and adult cancer specialists, and cancer
surgeons were considered (8).
Similar studies in the field of teleoncology for breast
cancer have focused on the final clinical results and com-
parison of these systems with face-to-face models. To our
knowledge, identifying the required data elements have
not been addressed in those studies (15, 16, 44). In our
study, experienced breast cancer specialists actively par-
ticipated in the identification of required data elements
for the teleoncology system, and their views and opinions
were applied.
It is worth noting that there was no consensus on some
data elements, which were identified necessary with a low
average percentage and due to patients’ clinical condi-
tions. For example, the existence of some data elements
including some tests (Mg, Pr), imaging (PET scan, simple
X-ray), and consultations (genetic counseling, psychiatric
counseling) did not appear to provide a treatment plan for
all patients.
Rudnisky et al. applied the clinical guidelines related
to imaging, presentation, and diagnostic grading in a
teleophthalmology system designed for diabetic retinopa-
thy (50). Furthermore, in the study conducted by Hazin
and Qaddoumi to investigate the current and future state
of teleoncology, the authors noticed that the Mexican Na-
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Table 5. Tests, Imaging, Patient Preferences, and Consultations
Category Data Elements Average (%) Necessary
17-Assess PD-L1 biomarker












145 Bill (total) 100























168 CT (neck, chest, abdomen, pelvis, brain, spine, etc.) 100
169 MRI (neck, chest, abdomen, pelvis, brain, spine, breast, etc.) 75
170 Sonography (abdomen, pelvis) 100
171 Sonography (breast) 100
172 Mammography 100
173 Bone scan 100
174 PET Scan 71.87
175 Simple X-ray (chest, spine, pelvis, etc.) 71.87
176 Important findings of imaging 87.50
20-Patient preferences and consultations
177 Fertility counseling 100
178 Cardiovascular counseling 100
179 Images of cardiovascular counseling 84.38
180 Genetic counseling 87.50
181 Psychiatric counseling 81.25
182 Patient preferences 100
Abbreviations: Alb, albumin; ALT, alanine transaminase; ALKP, alkaline phosphatase; AST, aspartate transaminase; Bill, bilirubin; Ca, calcium; CA125 , cancer antigen 125;
CA15-3 , cancer antigen 15-3; CEA, carcinoembryonic antigen; Cr, creatinine; ESR, erythrocyte sedimentation rate; FBS, fasting blood sugar; FSH, follicle-stimulating hor-
mone; Hb, hemoglobin; K, potassium; LDH, lactate dehydrogenase; LH, luteinizing hormone; Lymph, lymphocytes; Mg, magnesium; Na, sodium; Neut, neutrophils;
P, phosphorus; Plt, platelet; Pr, protein; WBC, white blood cell; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; β-HCG, beta-human chorionic
gonadotropin
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Table 6. Main Themes, Categories, and Sub-Categories of Extracted Requirements




Ability to register users in the system
Existence of user profile for each user in the system
Ability to edit user information registered in the system
Ability to verify the identity of users who register in the system
Ability to print documents and report in the system
Ability to support standard devices such as laptops and tablets
Ability to access the system through web browsers without the need to install on a specific platform or
operating system
Help for users to learn how to work with the system
Ability to search in the system
Operational requirements
special for physicians involved
in providing patient’s
treatment planning
Ability to create audio and video communication to discuss and consult with other physicians involved in the
treatment process
Ability to create audio and video communication with the patient
Ability to access to information and medical history of the patient through the system
Ability to access to patient’s medical images through the system
Ability to access to patient’s lab results through the system
Ability to access the results of the consultations and patient preferences through the system




Ability to create medical records for the patients
Ability to send patient medical records for specialists
Residents’ ability to access clinical information and provide treatment plans for educational purposes
Ability to send the provided treatment plan to the patient
Ability to record and access information and medical history of the patient through the system
Ability to record and access to patient’s medical images through the system
Ability to record and access to patient’s lab results through the system
Ability to record and access to results of the consultations and patient preferences through the systems
Operational requirements
special for patients
Ability to access patients’ medical records and provide treatment plans
Ability to access the patient’s medical images through the system
Ability to access the patient’s lab results through the system
Communication with other
information systems
Ability to connect to the Electronic Health Record (EHR) system for sending and receiving patient medical
records
Ability to connect to the Health Information System (HIS) for sending and receiving patient medical records
Ability to connect to information systems such as laboratory information systems or radiological information
systems if these information systems are separate from the hospital information system for sending and
receiving patient medical records





Safe login to /logout from the system
Defining the access level of users
Usability
User-friendly system
Easy training and learning of the desired operation in the system
The availability of the system for all users
Efficiency Appropriate response time for processing operations, communication, reporting, and data storage in the
system
Reliability and supportability
Ability to change and develop, configure and service the system
Appropriate response time when encountering an error
Appropriate response time to repair and update the system
Minimize the number and severity of system errors
tional Center for Health Technology Excellence has pro-
posed comprehensive clinical guidelines in the Spanish
language to be used in their telemedicine projects (46).
The results of studies indicate that applying the clinical
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guidelines in telemedicine programs is important and
valuable to provide quality healthcare services. In this re-
gard, the use of clinical guidelines for the development
of telemedicine systems has also been emphasized by
prominent telemedicine associations including the Amer-
ican Telemedicine Association (ATA) in various fields of
medicine (51). In addition to investigating the latest clini-
cal guidelines related to the treatment of breast cancer and
reviewing the patients’ medical records, the added value
of the present study aimed at identifying the required
data element is in applying the comments and sugges-
tions of breast cancer specialists at all stages. Finally, the
required data elements, identified by experts, were con-
firmed. Therefore, all the processes were performed sci-
entifically and by applying experts’ opinions in the field
of breast cancer treatment, thereby covering all aspects in
this regard.
The number of questions in the questionnaire (186
questions) was one of the limitations of the present study;
as the results of some studies show, using long question-
naires may reduce the accuracy of participants’ responses
and their willingness to participate in the study (52, 53).
However, reducing the number of questions might have
hindered us in achieving the main purpose of the study.
Therefore, we decided to decrease the effect of this lim-
itation by organizing the questions into several sections
based on the content and relevance of the items. More-
over, sufficient time was given to the participants, if they
needed, to complete the questionnaire. According to the
arrangements made with the participants, a text message
to complete the questionnaire was sent to them one day
before the visit.
5.2. Requirements Elicitation
As mentioned earlier, the interview method with end-
users was employed to determine the requirements of
the teleoncology system. Moreover, the questionnaire
containing pre-identified requirements was used during
the interview process. Considering the interviewees of
the study did not have practical experience of working
with telemedicine systems; the use of the questionnaire,
by which we had already identified some requirements,
helped guide the interviewees and identify the require-
ments by them. Similarly, interviews, questionnaires,
or a combination of these two methods have been ap-
plied in various studies to identify the requirements of
telemedicine systems (11, 54-56). Generally, the software re-
quirements are divided into 2 main categories, which are
functional and non-functional requirements (57). In this
regard, the requirements identified in the present study
were divided into two main functional and non-functional
themes, and each of these themes was classified and sub-
categories based on the analysis of the results of the inter-
views.
Since health information systems are more complex
than other information systems and have multiple users
with different levels of expertise and knowledge, one of the
best approaches to identify such systems require to engage
the users (28). Given that one of the aims of the present
study was to identify the requirements of the telemedicine
system to provide treatment plans for patients with breast
cancer, and typically a multidisciplinary team consisting
of various specialists is used to provide treatment plans for
breast cancer, they should be involved to identify the re-
quirements of such system. Indeed, one of the strengths
of the present study was the fact that the users participat-
ing in the interview process were from the different spe-
cialized disciplines, leading to a comprehensive examina-
tion of the requirements of the system from different per-
spectives.
The results of the present study in the functional re-
quirements section show that all participants remarked
that they needed to register in the system and have their
profiles to securely access the system and perform their du-
ties. In this regard, our results are in line with other stud-
ies, in which web-based telemedicine programs have been
applied (58, 59). In similar studies conducted in the field
of telemedicine, capabilities, and features such as the abil-
ity to upload medical images, search and report in the sys-
tem have been identified as the main requirements of such
systems (11, 12). According to the findings of the present
study, most of the interviewees mentioned that depending
on the patient’s condition, special medical images, which
could be uploaded, were needed. It is also necessary to pro-
vide the ability to search and report in the system for all
users of the system with different roles.
Some studies have shown that human error is one of
the major factors, leading to errors commonly observed in
telemedicine systems. This could be due to the inability of
users to use these systems. This problem can be resolved
by providing a help section to train users of telemedicine
systems (60, 61). Similar to other studies in this area (62-
64), providing a help section for users of the teleoncology
system is necessary to get informed about the capabilities
of the system and to learn how to work with the system.
There is evidence to suggest that connecting telemedicine
systems to other clinical information systems provide pos-
itive outcomes such as easy access to various types of pa-
tients’ medical information and minimizing the repeti-
tion of unnecessary tests and procedures (65, 66). Like-
wise, the results of our study show that communicating
the teleoncology system with other clinical information
systems is one of the requirements recommended by the
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interviewees.
The results of Alencar et al.’s systematic mapping re-
search on non-functional requirements in health informa-
tion systems show that the interview method is the most
widely used instrument to identify the non-functional re-
quirements in this area. The result of their research also
showed that security and privacy were observed more than
other non-functional requirements in studies (39). Some
of the non-functional requirements identified in health
care software systems include communicativeness, confi-
dentiality, integrity, efficiency, privacy, reliability, safety, se-
curity, traceability, and usability (67). In this regard, the
non-functional requirements resulting from the analysis
of interviews in our study were divided into 4 categories,
including security and privacy, reliability and supportabil-
ity, usability, and efficiency.
5.3. Conclusions
Based on the results of this study, identifying the re-
quired data elements for teleoncology systems is a key step
for implementing such systems. In this regard, as clini-
cal guidelines provide up-to-date and evidence-based in-
formation, it is recommended to use them to identify the
required data elements of telemedicine systems. Besides,
the data elements that are recorded in the patients’ med-
ical records for providing treatment plans in the conven-
tional model should also be examined. Finally, applying
the opinions and knowledge of medical professionals to
improve the process of identifying the required data ele-
ments is suggested.
Since the healthcare providers in various fields of on-
cology are potential users of such systems, developers
should consider users’ requirements and needs when de-
signing and developing telemedicine systems to increase
its acceptance and use. In this regard, the findings of the
present study can provide a fairly comprehensive view for
determining the requirements of teleoncology systems for
developers and researchers in their future research.
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